Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based triple therapy for resistant Helicobacter pylori infection in Egypt
PACTR202505820765765Phase 4Completed
- Sponsor
- Suez University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vonoprazan, amoxicillin and metronidazole in Helicobacter pylori infection, sponsored by Suez University. Primary endpoint: H. pylori eradication rate. Started Jan 2023; status: completed.
02
Drugs
vonoprazanamoxicillinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on PACTR202505820765765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505820765765.